Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Bulgaria: Pavulon; Cyprus: Pavulon; Czech Republic: Pavulon; Estonia: Pavulon; Finland: Pavulon; France: Pavulon; Germany: Pancuronium; Greece: Pancuronium, Pavulon; Italy: Pavulon; Luxembourg: Pavulon; Netherlands: Pavulon; Poland: Pancuromium; Romania: Pancuronium, Pavulon; Sweden: Pavulon; UK: Pancuronium.

North America

Canada: Pancuronium; USA: Pancuronium.

Latin America

Argentina: Bemicín, Pancurón, Pancuronio, Plumger; Brazil: Pancuron, Pavulon; Mexico: Bromurex, Pancuronio, Panlem.


Japan: Mioblock.

Drug combinations


Pancuronium Bromide: C~35~H~60~Br~2~N~2~O~4~. Mw: 732.67. (1) Piperidinium, 1,1′-[(2β,3α,5α,16β,17β)-3,17-bis(acetyloxy)androstane-2,16-diyl]bis[1-methyl]-, dibromide; (2) 1,1′-(3α,17β-Dihydroxy-5α-androstan-2β,16β-ylene)bis[1-methylpiperidinium] dibromide diacetate; (3) 2β,16β-Dipiperidino-5α-androstane-3α,17 β – diol diacetate dimethobromide. CAS-15500-66-0 (1971).

Pharmacologic Category

Neuromuscular Blocking Agents, Nondepolarizing. (ATC-Code: M03AC01).

Mechanism of action

Blocks neural transmission at myoneural junction by binding with cholinergic receptor sites.

Therapeutic use

Adjunct to general anesthesia to facilitate endotracheal intubation and relax skeletal muscles during surgery. To facilitate mechanical ventilation in intensive care unit.

Pregnancy and lactiation implications

Unlabeled use


Hypersensitivity to pancuronium, bromide, or any component of the formulation.

Warnings and precautions

Cross-sensitivity with other neuromuscular-blocking agents may occur (use extreme caution in previous anaphylactic reactions). Resistance may occur in burn patients (>30% of body) for period of 5-70 days postinjury. Alkalosis, hypercalcemia, demyelinating lesions, peripheral neuropathies, denervation, infection, muscle trauma, and diabetes mellitus may result in antagonism of neuromuscular blockade. Electrolyte abnormalities, severe hyponatremia, severe hypocalcemia, severe hypokalemia, hypermagnesemia, neuromuscular diseases, acidosis, acute intermittent porphyria, Eaton-Lambert syndrome, myasthenia gravis, renal failure, and hepatic failure may result in potentiation of neuromuscular blockade. Use with caution in hepatic or renal impairment, and in the elderly. Resistance may occur in immobilized patients.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart